|
mRNA target | DNAzyme | Animal | Xenograft | Dose regime | Outcome | Reference |
|
β1 integrin | β1DE | BALB/cA nude (nu-/-)-B6.Cg-Foxn1nu mice | PC-3 and CX1.1 | Intratumoral administration of 1.25 μg of β1DE every second day after the tumor volume reached 150 mm3 for three weeks | Inhibition of solid tumor growth | [26] |
β1 integrin | DEβ1 | BALB/cA nude (nu-/-)-B6.Cg-Foxn1nu mice | PC-3 and HT29 | Intratumoral administration of 1.25 μg of DEβ1 per tumor eight times every second day after the tumor volume reached 80-150 mm3 | Inhibition of solid tumor growth | [30] |
MMP-9 | AM9D | MMTV-PyMT transgenic mice | Breast tumor | When tumors were at early palpable size, intratumoral administration of 10 or 25 μg of AM9D once per week for four weeks | 39.5% and 50% reduction in tumor size, respectively, 77% reduction in MMP-9 mRNA level | [38] |
Egr-1 | ED5 | Athymic Balb/c nude mice | MCF-7 | Intratumoral administration of 20 μL of ED5 with 1 μL of FuGENE6 twice a week | Inhibition of solid tumor growth | [46] |
| DzF | Balb/c nude mice | MDA-MB-231 | When the tumors were palpable, intratumoral administration of 10 μg of DzF twice per week in an injectate volume of 10 μL | Inhibition of solid tumor growth | [50] |
VEGFR-1 | DT18 | Athymic nude mice | CNE1-LMP1 | When the tumor volume reached 60-100 mm3, intratumoral administration of 100 μg of DT18 with 3 μL of Fugene6, twice a week | Suppression of tumor growth, changes in tumor vasculature and vessel permeability | [53] |
VEGFR-2 | VEGFR2 DNAzyme | Athymic nude mice | MDA-MB-435 | When the tumor was visible, four intratumoral administrations consisting his-lys polymer with 2.9 μg of DNAzyme | 75% reduction in tumor growth, reduction in blood vessel density, cell death in tumor periphery | [59] |
c-jun | Dz13 | C57BL/J6 mice | B16F10 | Commencement of the experiment, subcutaneous administration of 200 μL of vehicle containing 750 μg of Dz13 and 2.5 μL of FuGENE6 twice per week | 60% reduction in tumor growth, inhibition of tumor vascular density | [58] |
| | Balb/c nude mice | SaOS-2 | When the tumors were palpable, intratibial administration of Dz13 at 0.8 μM and caspase-2siRNA at 4 μM in 50% Matrigel | Induction of caspase-2 expression | [60] |
| | Mice | SW872 | Commencement of the experiment, intramuscular administration of Dz13+FuGENE6 at an oligonucleotide concentration of 0.4 μM into the hind limb | Inhibition of tumor growth | [61] |
| | Severe-combined immunodeficient and C3H/Hen mice | T79 | After 15-20 days of dermal implantation, intratumoral administration of 20 and 40 μg of Dz13 with DOTAP and DOPE twice per week | Inhibition of tumor growth and suppression of neovascularization | [66] |
Bcl-xL | DT882 | Balb/c athymic nude mice | PC3 | When tumors reached 100-200 mm3, a dose rate of 12.5 mg/kg/d of saline solution containing DT882 over 14 days via a ALZET osmotic pump (BioScientific) | Inhibition of tumor growth and chemosensitization | [69] |
Aurora kinase A | DZ2 | Balb/c nude mice | PC3 | When the tumor reached about 65 mm3, intratumoral administration of 8 μg of DZ2 daily for 14 days | Inhibition of tumor growth | [78] |
Akt1 | Dz2 | Balb/c nude mice | CNE1-LMP1 | When the tumor volume reached 60-100 mm3, intratumoral administration of 10 μg of Dz2 with 3 μL of FuGENE6 twice per week | Inhibition of tumor growth. | [95] |
PKCα | DRz4 | Inbred B.D.-IX rats | BT4C | Single intracranial administration of 100 μg of DRz4 with 5 μL of saline | Enhancement of survivability of tested animals | [101] |
LMP1 | DZ509 | Balb/c nude mice | C666-1 | When tumor size reached 5-8 mm, intratumoral administration of 33 μg of DZ509 once per day for a week | Suppression of tumor growth | [117] |
| Dz1 | Athymic Balb/c nude mice | CNE1-LMP1 | When the tumor volume reached 60-100 mm3, intratumoral administration of 20 μL of Dz1 with 1 μL of FuGENE6 twice a week | Suppression of tumor growth and radiosensitization | [126] |
| Dz1 | Athymic Balb/c nude mice | CNE1-LMP1 | When the tumor volume reached 60-100 mm3, intratumoral administration of 100 μg of Dz1 with 3 μL of FuGENE6 once every three days | Suppression of tumor growth and radiosensitization | [132] |
|